<DOC>
	<DOCNO>NCT02182063</DOCNO>
	<brief_summary>The aim study evaluate efficacy two different dos BIBF 1120 ( 250 mg twice daily versus 150 mg twice daily ) exploratory manner . Safety , quality life pharmacokinetic parameter sub-sample 20 patient also analyse two different dos .</brief_summary>
	<brief_title>A Study With BIBF 1120 Patients With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>1 . Patient write informed consent obtain prior study procedure consistent ICHGCP ( International Conference Harmonization Good Clinical Practice ) guideline local law 2 . Presence histologically document adenocarcinoma prostate 3 . Presence metastatic disease 4 . Life expectancy least 3 month 5 . Progression orchidectomy LHRH ( Luteinising hormone release hormone ) analog castrate testosterone serum level &lt; 30 ng/ml ( chemical castration continue ) absence antiandrogen withdrawal syndrome 6 . Minimum value PSA = 20 ng/ml screen 7 . Stopping previous treatment docetaxel base regimen or/and antiandrogen 4 week inclusion patient 8 . ECOG performance status ≤ 2 9 . Progression one previous chemotherapy docetaxel base regimen : Appearance new lesion increase exist measurable / non measurable lesion Increase PSA ≥ 25 % document two successive exam Increase pain correlation radiological progression PSA increase define 10 . Adequate hepatic function : total bilirubin within normal limit , ALT ( Alanine aminotransferase ) and/or AST ( aspartate aminotransferase ) ≤ 1.5x upper limit normal ( ULN ) . Prothrombin time ( PT ) partial thromboplastin time ( PTT ) : maximum 50 % deviation normal limit 11 . Adequate renal function : serum creatinine ≤ 2 x upper normal limit ( UNL ) 12 . Absolute neutrophil count ( ANC ) ≥ 1500/mL , Platelets ≥ 100,000/mL , Hemoglobin ≥ 9.0 g/dL ( hemoglobin may support transfusion erythropoietin approve hematopoietic growth factor ) 1 . Gastrointestinal disorder abnormality would inhibit absorption study drug 2 . Serious illness concomitant nononcological disease neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study 3 . Significant cardiovascular disease ( i.e . uncontrolled hypertension , instable angina , history myocardial infarction congestive heart failure &gt; NYHA II ( New York Heart Association ) 6 previous month 4 . Strontium equivalent radioactive isotope 6 previous month 5 . Concomitant second malignancy , exception treat basal cell carcinoma skin recover cancer least since 5 year 6 . Major injury surgery within past 4 week . Planned surgical procedure trial . Patients incomplete wound heal 7 . History haemorrhagic emerge thrombotic event . Known inherited predisposition hemorrhage thrombosis 8 . Patients require fulldose anticoagulation heparinization continuous treatment acetylsalicyclic acid &gt; 325 mg 9 . Concomitant treatment experimental drug anticancer therapy include hormone therapy ( except LHRH agonist ) 10 . Biphosphonates study since four week prior inclusion patient 11 . Known suspected symptomatic brain metastasis 12 . Known suspected symptomatic epiduritis 13 . Treatment investigational drug participation another clinical trial within past four week start therapy ( visit 2 ) concomitantly trial 14 . Patients unable comply protocol</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>